Neha Patil

Darifenacin

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Trade names  Enablex
MedlinePlus  a605039
ATC code  G04BD10 (WHO)
CAS ID  133099-04-4
AHFS/Drugs.com  Monograph
Routes of administration  Oral
Molar mass  426.55 g/mol
Protein binding  98%
Darifenacin
Pregnancy category  AU: B3 US: C (Risk not ruled out)

How to pronounce darifenacin enablex memorizing pharmacology flashcard


Darifenacin (trade name Enablex in US and Canada, Emselex in Europe) is a medication used to treat urinary incontinence. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010 the US rights were sold to Warner Chilcott for 400 million US$.

Contents

Darifenacin uses reviews side effects and contraindications


Mechanism of action

Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

It should not be used in people with urinary retention. Anticholinergic agents, such as darifenacin, may also produce constipation and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment.

Clinical uses

Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults.

References

Darifenacin Wikipedia


Similar Topics
Loves Blindness
Karen Olsson
Rodney Smithson
Topics